Urinary albumin excretion is associated with pulmonary hypertension in sickle cell disease: potential role of soluble fms-like tyrosine kinase-1

被引:45
|
作者
Ataga, Kenneth I. [1 ,2 ]
Brittain, Julia E. [2 ,3 ]
Moore, Dominic [4 ]
Jones, Susan K. [1 ,2 ]
Hulkower, Ben [2 ]
Strayhorn, Dell [1 ,2 ]
Adam, Soheir [1 ,2 ]
Redding-Lallinger, Rupa [2 ,5 ]
Nachman, Patrick [6 ]
Orringer, Eugene P. [1 ,2 ]
机构
[1] Univ N Carolina, Div Hematol Oncol, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Comprehens Sickle Cell Program, Chapel Hill, NC 27599 USA
[3] Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA
[4] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA
[5] Univ N Carolina, Dept Pediat, Chapel Hill, NC 27599 USA
[6] Univ N Carolina, Div Nephrol & Hypertens, Chapel Hill, NC 27599 USA
关键词
hemophilia A; mutations; structure-function; factor VIII; GROWTH-FACTOR RECEPTOR; 3RD NATIONAL-HEALTH; RISK-FACTORS; RENAL-FUNCTION; CHILDREN; MICROALBUMINURIA; ADULTS; PREVALENCE; FAILURE; ANEMIA;
D O I
10.1111/j.1600-0609.2010.01471.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Hemophilia A (HA) is a common X-linked recessive bleeding disease caused by mutations in FVIII gene. The identification of mutation in HA subjects can lead to more accurate diagnosis and contribute to the genetic counseling/prenatal diagnosis. Objectives: Our objective is to identify the FVIII defects in 148 unrelated Chinese HA subjects and to analyze the potential consequence of novel mutations. Methods: FVIII: C was assayed using one-stage method, and FVIII inhibitor was tested using Bethesda method. Intron 22 and 1 inversions were identified by PCR technique. Non-inversion mutations of FVIII gene were identified by direct sequencing. Novel mutations were further analyzed based on a B-domain deleted FVIII crystallographic structure and bioinformatics tools. Results: The intron 22 and 1 inversions affected 57 and three severe subjects, respectively. Sixty-seven different mutations were identified in non-inversion subjects including 35 novel mutations that were not reported previously. Novel mutations include five nonsense mutations, 15 missense mutations, three insertions, eight small deletions, two splice site mutations and two partial gene deletions. The potential deleterious effects of these novel missense mutations include disruption of the protein core, impairment of inter-domain interaction and FVIII binding with other proteins. Conclusion: Similar to other races, intron 22 and one inversions are also recurrent mutation in severe HA subjects monitored in our centre. Sixty-seven mutations (52% novel reported) among 88 non-inversion subjects represent the high degree of heterogeneity of FVIII gene mutations causing HA. Characteristic of HA FVIII gene mutations extend our insight into structure-function relationship of the FVIII molecule.
引用
收藏
页码:257 / 263
页数:7
相关论文
共 50 条
  • [21] Soluble fms-like tyrosine kinase-1 (sFlt-1) localization in renal biopsies
    Zsengeller, Zsuzsanna Kinga
    Tavasoli, Mahtab
    Pernicone, Elizabeth
    Karumanchi, Ananth Subbian
    Rosen, Seymour
    FASEB JOURNAL, 2018, 32 (01):
  • [22] Soluble Fms-like tyrosine kinase-1 polymorphisms associated with severe-spectrum hypertensive disorders of pregnancy
    Chen, Tracy
    Baldauf, Claire E.
    Gill, Kevin S.
    Ingles, Sue Ann
    Pickering, Trevor A.
    Wilson, Melissa L.
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2025, : 609 - 619
  • [23] Soluble Fms-Like Tyrosine Kinase-1 Alters Cellular Metabolism and Mitochondrial Bioenergetics in Preeclampsia
    Sanchez-Aranguren, Lissette C.
    Espinosa-Gonzalez, Cindy T.
    Gonzalez-Ortiz, Laura M.
    Sanabria-Barrera, Sandra M.
    Riano-Medina, Carlos E.
    Nunez, Andres F.
    Ahmed, Asif
    Vasquez-Vivar, Jeannette
    Lopez, Marcos
    FRONTIERS IN PHYSIOLOGY, 2018, 9
  • [24] Soluble fms-like tyrosine kinase-1 antibody for diagnosis purposes (WO2010075475)
    Boyaud, France
    Inguimbert, Nicolas
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2011, 21 (06) : 971 - 975
  • [25] SOLUBLE FMS-LIKE TYROSINE KINASE-1 IN CHILDREN AND ADOLESCENTS WITH THALASSEMIA INTERMEDIA: RELATION TO PULMONARY VASCULOPATHY AND SUBCLINICAL ATHEROSCLEROSIS
    Tantawy, A.
    Adly, A. A.
    Ismail, E.
    Yousef, O.
    Ali, M.
    HAEMATOLOGICA, 2015, 100 : 620 - 620
  • [26] Reduction of Circulating Soluble Fms-Like Tyrosine Kinase-1 Plays a Significant Role in Renal Dysfunction-Associated Aggravation of Atherosclerosis
    Onoue, Kenji
    Uemura, Shiro
    Takeda, Yukiji
    Somekawa, Satoshi
    Iwama, Hajime
    Imagawa, Keiichi
    Nishida, Taku
    Morikawa, Yoshinobu
    Takemoto, Yasuhiro
    Asai, Osamu
    Soeda, Tsunenari
    Okayama, Satoshi
    Ishigami, Kenichi
    Nakatani, Kimihiko
    Kawata, Hiroyuki
    Horii, Manabu
    Nakajima, Tamio
    Akai, Yasuhiro
    Iwano, Masayuki
    Saito, Yoshihiko
    CIRCULATION, 2009, 120 (24) : 2470 - 2477
  • [27] Disulfiram inhibits placental soluble FMS-like tyrosine kinase-1 and soluble endoglin secretion independent of the proteasome
    Hastie, Roxanne
    Ye, Louie
    Hannan, Natalie J.
    Brownfoot, Fiona C.
    Cannon, Ping
    Nguyen, Vi
    Tong, Stephen
    Kaitu'u-Lino, Tu'uhevaha J.
    PREGNANCY HYPERTENSION-AN INTERNATIONAL JOURNAL OF WOMENS CARDIOVASCULAR HEALTH, 2018, 14 : 125 - 130
  • [28] Soluble fms-like tyrosine kinase-1: a potential early predictor of respiratory failure in COVID-19 patients
    Eguiburu-Jaime, Jose L.
    Delmiro, Aitor
    Lalueza, Antonio
    Valenzuela, Pedro L.
    Aguado, Jose M.
    Lumbreras, Carlos
    Arenas, Joaquin
    Martin, Miguel A.
    Lucia, Alejandro
    Lopez-Jimenez, Elena A.
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2021, 59 (07) : E289 - E292
  • [29] The relationship between circulating endothelin-1, soluble fms-like tyrosine kinase-1 and soluble endoglin in preeclampsia
    P K Aggarwal
    N Chandel
    V Jain
    V Jha
    Journal of Human Hypertension, 2012, 26 : 236 - 241
  • [30] The relationship between circulating endothelin-1, soluble fms-like tyrosine kinase-1 and soluble endoglin in preeclampsia
    Aggarwal, P. K.
    Chandel, N.
    Jain, V.
    Jha, V.
    JOURNAL OF HUMAN HYPERTENSION, 2012, 26 (04) : 236 - 241